ERK5 also mediates CML cell resistance to imatinib, with Erk5 deletion significantly impeding the cell cycle progression in imatinib-treated cells [97]. This evidence concerns the gene MAPK7 and chronic myelogenous leukemia, BCR-ABL1 positive.